American Society of Hirudotherapy

Lichen Sclerosus (Investigational Adjunct)

Highly investigational adjunct for refractory anogenital lichen sclerosus; no RCT evidence; potent topical corticosteroid (clobetasol) remains standard of care.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for lichen sclerosus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for lichen sclerosus is investigational.
What evidence exists?
Tier C (investigational). Only case reports; there are no randomized controlled trials. Evidence-based therapy for lichen sclerosus is ultra-potent topical corticosteroid (clobetasol propionate 0.05% once daily for 3 months, then maintenance) per AAD/BSGE guidelines. Topical calcineurin inhibitors as steroid-sparing. Vulvar disease requires gynecologic monitoring for squamous cell carcinoma risk (3-5 percent lifetime).
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of fragile lichen sclerosus skin with trauma
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Triggering of new lichen sclerosus lesions at bite sites (Koebner phenomenon)
  • Scarring or distortion in fragile genital tissue
  • Delay of clobetasol therapy and gynecologic SCC monitoring
  • Risk of missed early squamous cell carcinoma in untreated disease
Who should not consider this
  • Patients with vulvar lichen sclerosus (gynecologic specialty care required)
  • Patients with penile lichen sclerosus (urology referral)
  • Patients with suspected squamous cell carcinoma (biopsy mandatory)
  • Patients with active erosions, ulceration, or bleeding lesions
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not used clobetasol 0.05% consistently for 3 months
What to ask your clinician
  • Has the diagnosis been confirmed by biopsy?
  • Have I been screened for squamous cell carcinoma risk?
  • Have I used clobetasol propionate 0.05% as directed for 3 months?
  • Am I being monitored by a gynecologist or urologist for genital disease?
  • What evidence specifically supports leech therapy for lichen sclerosus?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • New ulceration, persistent erosion, or new firm lump at any lichen sclerosus site (rule out SCC)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Severe genital pain, bleeding, or urinary obstruction
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for lichen sclerosus.
  • Case reports do NOT establish efficacy versus clobetasol 0.05%, the gold-standard treatment.
  • It does NOT mean genital lichen sclerosus is appropriate for hirudotherapy — gynecologic or urologic specialty care is essential.
  • It does NOT substitute for SCC screening — lichen sclerosus has a 3-5 percent lifetime SCC risk.
  • It does NOT mean leech application is safe on fragile, atrophic, or eroded skin.

Clinical Profile

Category
dermatological
ICD-10
L90.0
Safety tier
high

Evidence Summary

Lichen sclerosus is a chronic inflammatory dermatosis with sclerotic dermal change and a risk of squamous cell carcinoma in long-standing untreated disease. Standard of care per BAD and AAD guidance is an ultra-potent topical corticosteroid (clobetasol propionate 0.05%) with long-term maintenance, plus regular surveillance. No controlled clinical trial of leech therapy for lichen sclerosus has been published; its use is investigational and mechanistic only. Direct anogenital application is contraindicated due to mucosal anatomy, infection risk, and lack of evidence. Patients must remain under dermatology follow-up for malignancy surveillance regardless of any adjunctive therapy. Evidence is grade D.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Michalsen A (2007)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Anogenital placement of any kind
  • Active vulvar or penile intraepithelial neoplasia
  • Suspected squamous cell carcinoma in any lichen sclerosus plaque
  • Discontinuation of prescribed topical corticosteroid maintenance

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Lichen Sclerosus (Investigational Adjunct) — Hirudotherapy Evidence | ASH